EP Wealth Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

EP Wealth Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,038	Closed	-$240K	–	1509
2025 Q4	$240K	Buy	+4,038	New	+$220K	﹤0.01%	1267
2025 Q2	$434K	Buy	7,899 +1,269	+19%	+$74.7K	﹤0.01%	839
2025 Q1	$469K	Sell	6,630 -513	-7%	-$34.5K	﹤0.01%	734
2024 Q4	$470K	Buy	7,143 +24	+0.3%	+$1.61K	﹤0.01%	712
2024 Q3	$500K	Buy	+7,119	New	+$595K	﹤0.01%	693

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EP Wealth Advisors's BMRN Position: Q1 2026 in Review

EP Wealth Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 4,038 shares — an estimated $240K sold.

EP Wealth Advisors first reported a position in BMRN in Q3 2024 and held it in 5 quarters. The position peaked at $500K in Q3 2024. 559 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

EP Wealth Advisors reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
EP Wealth Advisors sold 4,038 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $240K.
EP Wealth Advisors first reported a position in BioMarin Pharmaceuticals in Q3 2024 and held it in 5 quarters.
EP Wealth Advisors's BioMarin Pharmaceuticals position peaked at $500K in Q3 2024.
559 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on EP Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.